Sponsor:
Convergent Therapeutics
Code:
NCT06549465
Conditions
PSMA PET-Positive Castration-Resistant Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
In-111 rosopatamab tetraxetan
45 kBq/kg Ac-225 rosopatamab tetraxetan
55 kBq/kg Ac-225 rosopatamab tetraxetan
60 kBq/kg Ac-225 rosopatamab tetraxetan
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-24. This information was provided to ClinicalTrials.gov by Convergent Therapeutics on 2025-04-06.